Company Overview - Codexis has revenue-generating Pharma BioCatalysis solutions and RNA Manufacturing Solutions[5] - The company aims for cash flow positivity by the end of 2026[5] - Codexis has $60 million in cash/cash equivalents and investments as of March 31, 2025[5] RNA Manufacturing Solutions & ECO Synthesis - The ECO Synthesis toolbox is designed to meet future demand for RNAi therapeutics[5] - The ECO Synthesis platform enables enzymatic synthesis of RNAi therapeutics[10] - The company has signed the first revenue-generating contract for ECO Synthesis manufacturing services[42] - The ECO Synthesis platform could potentially reduce CapEx by 70% compared to phosphoramidite chemistry[48] RNAi Therapeutics Market - There are 7 approved siRNA therapies across multiple indications[23] - Over 400 total siRNA pipeline programs exist, with ~90% in Preclinical & Phase I stages[29, 30] - Chemical synthesis requires $725 million to produce 1K kg of RNAi per year[35]